Clinical-stage Focus Target cardiopulmonary and cardiac disease opportunities by aligning BD efforts with Bellerophon’s INOpulse platform and portable inhaled nitric oxide delivery system, emphasizing unmet clinical needs and potential partnerships or licensing deals for novel delivery across PAH, COPD-related PH, and ILD-associated PH.

Strategic Partnerships Leverage their board and leadership changes to position co-development or financing arrangements with investors and strategic pharma players seeking early-stage assets; highlight Bellerophon’s NASDAQ listing and IND-ready candidates as potential collaboration or funding catalysts.

Clinical Pipeline Identify opportunities to accelerate via clinical development partnerships around INOpulse product candidates, offering mid-stage trial support, diagnostics collaboration, or companion device integration to broaden the addressable market in cardiopulmonary indications.

Resource-lean Model Prospect as a fit for deal structures that minimize upfront risk for a small team: milestone-driven partnerships, royalty-like economics, or out-licensing of certain territories to reduce burn while advancing pipeline through external funding and CRO-enabled execution.

Market Readiness Position solutions to complement existing pulmonary and cardiovascular therapies; explore integration with specialty clinics and hospital systems that manage PAH and PH comorbidities, offering device-enabled nitric oxide delivery as a value-add to standard care.